Cleveland biotech Athersys raises $65M with reverse-merger
Athersys, a Cleveland, Ohio biotech, went public via reverse merger and raised $65 million in a private placement. The company’s release is here.
Founded in 1995, Athersys is active in a bewildering number of areas. Its lead product candidate is an appetite-suppressing drug that acts on a serotonin receptor in the brain called 5HT2c, and in general the company describes itself as focused on metabolic and neurological conditions. But it is also at work on an adult-derived stem-cell treatment for heart disease, stroke and bone-marrow transplant patients. None of these products, however, appear to be in human trials yet, which is sort of intriguing given how long the company has been around.
It turns out that Athersys is also a biotech chameleon. In 2000, it filed to raise $115 million in an IPO. According to its S-1 registration statement, the company was then a “functional genomics” company, which essentially means it surveyed large numbers of genes in an attempt to determine their function. Although popular during the genomics bubble of 1999-2000, this sort of business tended not to pan out for many companies. Athersys withdrew its proposed IPO six months after it was filed.
The Athersys funding was led by Radius Ventures, joined by OrbiMed Advisors, RA Capital Management, Accipiter Capital Management, Hambrecht & Quist Capital Management, MPM BioEquities, and Pappas Ventures.
Next Story: Topical drug maker Zars files for $86M IPO
Previous Story: Stealthy device maker Thermocure pulls in $125,000
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
-
David Hamilton